C
The Clorox Company
CLX · Consumer Defensive
Q2 FY2026
Earning ended Dec 31, 2025Report generated Mar 15, 2026
The Bleach Brand Is Bulletproof; Everything Around It Is Not
The market has correctly de-rated Clorox for its growth problems, but may be underappreciating that the 'recovery' in earnings and cash flow is predominantly a cyberattack-base-effect unwind rather than evidence of restored operational momentum — and the Gojo acquisition, announced while core household margins are barely above zero, is adding balance sheet risk at precisely the wrong point in the deleveraging cycle.
Flowly Score
Apr 16 Close
+3%$102.38
Fair Value
$105.00
50
Averageat $102.38
Business Strength6/10
The bleach brand is genuinely exceptional — it became a verb, and that category-ownership status has survived decades of private-label assault — but the portfolio is a mosaic of uneven moat quality, and management's supplement misadventure followed by the cyberattack operational failure reveal execution limitations that discount the otherwise-strong franchise. Elite ROIC confirms the core brands earn real economic rents, but the reinvestment runway is narrow and the portfolio carries ballast brands alongside the jewels.
Financial Resilience6/10
The cash generation is unambiguously real — operating cash flows consistently exceed reported earnings, and the business threw off meaningful free cash flow even through the cyberattack disruption, which is the highest-stress test a cash machine can face. The debt load is real and the balance sheet lacks the fortress quality the core brand deserves, but the Piotroski and Altman readings reflect a business in recovery, not distress, and the modest capex requirements mean free cash compounds into deleveraging capacity.
Growth & Trajectory4/10
Revenue has essentially flatlined for five years, and the triple-digit earnings recovery in 2025 is a base-effect illusion — you're comparing against an artificially crushed year, not witnessing a genuine demand reacceleration. Category growth of zero to one percent, simultaneous volume and pricing compression in household products, and a quietly shrinking international footprint paint the honest picture: this is a stalwart in deceleration, not a franchise finding new gear.
Valuation6/10at $110.68
The current price sits meaningfully above the neutral DCF scenario and requires sustaining growth assumptions that the underlying revenue trajectory actively contradicts — yet the de-rated multiple and a respectable free cash flow yield mean it isn't absurdly priced either. This is the definition of fairly valued with a slight lean toward expensive when growth assumptions are stress-tested honestly.
Risk5/10
No existential threats — bleach is not going out of style, and private label has been trying and mostly failing to dislodge the core franchise for decades — but several compounding pressures are running simultaneously: the Gojo acquisition adds meaningful leverage to an already-stretched balance sheet at the exact moment household segment margins are printing at crisis levels, and the pattern of management underestimating execution risk in adjacent categories is now a documented, repeated characteristic rather than a one-time event.
The investment case hinges on a tension that the valuation doesn't fully resolve: the core Clorox cleaning franchise is a genuinely rare asset — a brand so synonymous with its category that decades of private-label investment haven't meaningfully dented its shelf position — yet the current price sits above the neutral intrinsic value estimate and demands a sustained FCF growth rate that the flat-to-negative revenue trajectory simply doesn't support. You're paying a fair-to-slightly-premium price for a stalwart at the exact moment its underlying volume story is weakest. The direction of travel is the harder question. The cyberattack recovery is nearly complete, the ERP transition clears fully by fiscal Q4, and Clorox will likely report a clean year in 2027 — those tailwinds are real but mechanical, not evidence of a business getting structurally stronger. The Gojo acquisition is the genuine swing variable: Purell is a category-defining brand in a high-frequency consumer staple, and if management can integrate without operational distraction, it adds a legitimate growth asset. But the same management team that bought commodity supplement brands and then couldn't ship bleach for three months is now executing a major acquisition while the household segment is bleeding margin — integration optimism must be discounted accordingly. The single most specific risk is the retailer leverage dynamic in the household segment, where Glad trash bags and the cat litter portfolio are fighting for shelf space against increasingly aggressive retailer house brands with thin EBIT margins that leave almost no room to fund a promotional defense. If Walmart or Target decides shelf economics favor their own products in those categories — and household EBIT margins at five percent suggest the math is already borderline — Clorox loses negotiating leverage precisely where it can least afford to, and the volume losses compound into the FCF recovery story before it fully plays out.